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DOI 10.1016/j.chembiol.2009.08.005A new Seattle startup currently has just
four employees, but big plans. Arzeda,
a company spun out of the technology
developed at the laboratory of University
of Washington researcher David Baker,
PhD, is making plans to move out of the
UW launch center and into their own labo-
ratories. Their aim is to design and create
catalytic enzymes that are not found in
nature but that have the ability to tackle
a variety of big, real-world issues.
Popular at Meetings
‘‘When we developed our methods for
designing catalysts for, in principle, any
arbitrary chemical reaction, it was clear
there were lots of possible applications,’’
says David Baker, UW Professor of
Biochemistry, and Arzeda Scientific Advi-
sory Board (SAB) member. ‘‘I went to an
enzyme engineering meeting [that].was
largely attended by companies and I was
approached by a lot of people each
with a collaboration they wanted to do.’’
But Baker’s funding prohibits company-
sponsored research. ‘‘So we thought we
should start a company that could then
design enzymes for the many different
chemical reactions involved in so many
areas of life. If we were going to apply
these methods seriously to real-world
problems, we would need to move outside
the academic lab.’’ The idea—and the
opportunity—for Arzeda were conceived.
Active Sites Decorated with
Functional Groups
Designing any type of protein from
scratch is an achievement. This method-
ology has only matured in the last 5–10
years. Baker’s lab showed in 2003 that
they could design new proteins from
scratch that were unrelated to existing
proteins (Kuhlman et al., 2003). But the
protein generated, ‘‘Top7,’’ was nonfunc-
tional. ‘‘In the last 6 years, we have been
focused on methods to design new pro-
tein functions, like enzymes,’’ says Baker.
Baker’s group starting cooking up
novel enzymes by essentially working
backward from the traditional way of pro-
tein engineering: ‘‘First, we started with
a chemical reaction of interest and literally
drew in the ideal positions of the catalytic
groups—a hydrogen bond here, ring
there, negative charge here—but with no
enzyme yet,’’ he says. ‘‘It is essentially a
disembodied active site. Then you have
to design a protein that has that active
site.’’
The basic process starts with an under-
standing of a desired chemical reaction.
From that understanding, the first step in
the process is to design the active site:
the minimal active site. What it contains
is the transition state and the minimal
functional groups around that transition
state required to achieve a desired re-
action. ‘‘Then, using computation, those
active sites are mixed and matched with
a virtual library of over 200 protein scaf-
folds, looking for the right fit within those
scaffolds and the right geometric place-
ment of that active site in the scaffold,’’
explains Michael Martino, Arzeda CEO.
‘‘This is a 3D modeling exercise.’’
Landmark Publications
Fueling interest in Baker’s work and the
development of Arzeda was the 2008
publication of two papers highlighting
the de novo synthesis of two enzymes.
‘‘It has been very difficult to make cata-
lysts for any different reaction because to
We see the real opportunity in enabling reactions that can’t be
achieved today with the enzymes that exist in nature.
Michael Martino, Arzeda CEOChemistry & Biology 16, August 28, 200design an enzyme means you have to
control the position of many, many atomic
groups,’’ says Baker. ‘‘That is something
people have not been able to do until
recently.’’ In a 2008 Science paper,
Baker’s group showed just that. ‘‘We de-
signed retro-aldolases that use four dif-
ferent catalytic motifs to catalyze the
breaking of a carbon-carbon bond in
a nonnatural substrate,’’ explains the
study authors (Jiang et al., 2008). This
work was quickly followed by another
groundbreaking paper in Nature (Rothlis-
berger et al., 2008). Here the, team de-
scribed the computational design of eight
enzymes that use two different catalytic
motifs to catalyze the Kemp elimination:
a model reaction for proton transfer from
carbon. ‘‘This involved extracting a proton
away from a carbon, which is a very
widespread feature of catalysis,’’ explains
Baker. ‘‘You take the hydrogen away from
the carbon and it’s activated to do all
kinds of things.’’
But the problem easily acknowledged
by Baker is that the designed enzymes,
although they have function, do not oper-
ate with the efficiency of enzymes found in
nature. He has described it as the prover-
bial tortoise running the race. However,
pending publications will show that the
Baker lab has since boosted the function-
ality and speed of new enzymes. ‘‘We
have a considerably faster tortoise now,’’
he says. ‘‘In at least one case, it isn’t
winning the race, but it’s in the lead pack.’’
Rosetta
To handle the monumental computational
requirements of the enzyme design pro-
gram, Baker’s lab designed the Rosetta
computer program to do the prediction
and design calculations. ‘‘With this work,
the design problem is saying ‘here is the
ideal structure of an enzyme, now go
find a sequence that will fold up to
that,’’’ says Baker.
The Rosetta program is an open-source
algorithm for predicting how a unique9 ª2009 Elsevier Ltd All rights reserved 795
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protein’s characteristic shape. Rosetta
helps determine which folded shape will
be most stable, meaning it rests in a lower
energy state and can be more efficient.
‘‘Suppose we want to predict the struc-
ture of a protein, with Rosetta we give it
the sequence and the computers fold up
the protein into many possible solutions,’’
explains Baker. ‘‘With more than 100K
participants volunteering their computer
down-time to the Rosetta at Home effort,
their computers fold up the protein and
send us back the result so we get hun-
dreds of thousands different possible
solutions.’’
Adds Martino, ‘‘I think what made Ro-
setta particularly powerful and unique is
that the library that it generated consisted
mostly of folded stable proteins.’’
Ag-Bio First on Deck
Arzeda’s three cofounders emigrated
from the Baker lab where they were all
pivotal players in the enzyme creation
technology. Alexandre Zanghellini has a
background in computational science;
Daniela Grabs’ is in protein and antibody
design; Eric Althoff is chemist by training
with special experience in moving cata-
lytic antibody technology to proteins.
The 2008 Science and Nature papers
drew a lot of attention from commercial
players, including DuPont’s Pioneer Hi-
Bred Division, an ag/bio division in the
genetically-modified seed business. ‘‘Ar-
zeda will design enzymes to achieve
specific things within seeds,’’ says Mar-
tino. ‘‘Pioneer will then modify the ge-
nome of the seeds to express those
enzymes.’’ The overall objective is higher
yields for crops including corn, soybeans,
rice, cotton and canola.
‘‘What is truly impressive about this
technology is the sheer size of the libraries
that are generated and the ability of the
technology to filter that down to the top
100 candidates,’’ adds Martino. Typically
the group designs active motifs four at
a time. In combining the 4 active motifs
with over 200 protein scaffolds about
1050 possible enzyme candidates are
created. ‘‘The beauty of this is we are
doing it computationally in about a 4-6
week period of time,’’ says Martino. ‘‘It
would take years and years and years to796 Chemistry & Biology 16, August 28, 200get that number of candidates in the tradi-
tional directed evolution lab.’’ From 1050,
the software filters it down in an interme-
diate step to 106 candidates. The objec-
tive is to get it down to the top 100. ‘‘Liter-
ally what we have at that point are 100
enzyme candidates in the form of a
sequence of amino acids,’’ adds Martino.
Arzeda then expresses them using stan-
dard expression technology and then
assays them to determine both expres-
sion and activity.
Arzeda’s ultimate business goal is to
provide that fully validated enzyme.
Bioremediation and Drug Therapy
‘‘We truly believe this is an enabling
breakthrough technology,’’ says Martino.
Arzeda has its eye on two other areas
where it hopes to leverage its ability to
design active sites that don’t exist in
nature. ‘‘We look to the renewable chem-
ical space along the lines of biomass
conversion,’’ says Martino. ‘‘We think we
can provide tools to biorefineries and
chemical refineries that give them more
efficient and effective use of the biomass
conversion they are doing.’’ Baker is
more to the point: ‘‘We want to see this
technology used in bioremediation, to
break down toxic compounds in the
environment.’’
Beyond that, Arzeda looks to the phar-
maceutical sector to make big contri-
butions. Baker’s lab is already making
strides in both of those areas, with expec-
tations that they will be commercially
explored within Arzeda. ‘‘With therapeu-
tics, we would like to see this technology
used to enzymatically destroy toxic com-
pounds in your body or for a new way to
do gene therapy or for making novel vac-
cines,’’ says Baker. The UW group cur-
rently has a large HIV vaccine program.
‘‘While the technology can also be used
to optimize existing enzymes, and in fact
has been applied to that, we see the real
opportunity in enabling reactions that
can’t be achieved today with the enzymes
that exist in nature,’’ summarizes Martino.
CalTech, Duke, Monsanto
in the Game
The Baker lab has designed over 70
enzymes with good levels of starting
activity, but they are not the only ones in9 ª2009 Elsevier Ltd All rights reservedthe game. Stephen Mayo at the California
Institute of Technology and Homme Hel-
linga at Duke University are also involved
in the de novo enzyme and protein
creation space. Baker, Mayo, and Hel-
linga run the three best-known academic
groups in the country for computational
protein design.
It is no surprise to see Mayo and Hel-
linga expanding into the commercial
realm as well. What is interesting is that
the two have done so together. As of
June 2009, the two researchers joined
commercial efforts to form their own
company, Protabit LLC. ‘‘Steve and I
formed the company to do computational
protein design,’’ says Hellinga. ‘‘We are
developing a software suite to capture
the best practice design approaches.’’
Protabit’s mission will be to develop new
computational methods for improving
protein design. Potential end goals in-
clude new proteins or ‘‘reengineered’’
proteins, according to Hellinga.
Seemingly walking in lockstep, Prota-
bit’s first partnership is with Monsanto,
again focused on the biotech crop busi-
ness. ‘‘Agricultural biotechnology is just
one field of application,’’ says Hellinga.
‘‘It just turns out that the two major players
in that business think this is an important
area to go into and they see a future in it.’’
So, academic competitors are now
commercial competitors as well. Just as
Baker, Mayo, and Hellinga strive for first
in publication, now their commercial
offspring in Arzeda and Protabit will strive
for first to market. Place your order.
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